NOVARTIS

TAF + MEK ® Glioma

Image

Image

- Indication

- Prognosis

- Dosing

TAFINLAR + MEKINIST is the first and only† targeted treatment regimen for low- and high-grade paediatric glioma with BRAF V600E mutations

†As of July 2025.

Image

Low-grade glioma[1,2]

Treatment of paediatric patients ≥1 year of age with low-grade glioma with a BRAF V600E mutation who require systemic therapy

Learn more

Image

High-grade glioma[1,2]

Treatment of paediatric patients ≥1 year of age with high-grade glioma with a BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options

Learn more

- Indication

- Prognosis

- Dosing

BRAF V600E+ mutation is common in paediatric glioma and typically has a poor prognosis

Image

Low-grade glioma
Up to 20% paediatric of low-grade glioma patients will have a BRAF V600E mutation[3]

High-grade glioma
Up to 10% of paediatric high-grade glioma patients will have a BRAF V600E mutation[4]

Poorer response to current standard of care
Paediatric patients with glioma and a BRAF V600E mutation have poorer response to chemotherapy, resulting in shorter PFS and OS[5]



Image

Test early for the BRAF V600E+ mutation via genetic testing to give paediatric patients and their caregivers new hope for low- and high-grade glioma treatment

- Indication

- Prognosis

- Dosing

Flexible, weight-based dosing with paediatric-friendly formulations

TAFINLAR + MEKINIST is an oral regimen with weight-based dosing for paediatric patients (aged ≥1 year) with low- and high-grade glioma from 8 kg.[1,2] TAFINLAR is available in capsules or dispersible tablet forms, and MEKINIST is available as tablets or powder for oral solution.[1,2]

Capsule and tablet formulation (patients weighing ≥26 kg)[1,2]

Image



Oral suspension and solution formulation (patients weighing ≥8 kg)[1,2]

Image

Dosing for capsules and tablets administration (patients weighing ≥26 kg)

Recommended weight-based dosing and dose reductions for TAFINLAR capsule administration[1]

Image

TAFINLAR

Body Weight	Recommended Paediatric Dose (BID)	First Dose Reduction (BID)	Second Dose Reduction (BID)	Third Dose Reduction(BID)
26 to 37 kg	75 mg (one 75 mg capsule)	50 mg	–	–
38 to 50 kg	100 mg (two 50 mg capsules)	75 mg	50 mg	–
≥51 kg	150 mg (two 75 mg capsules)	100 mg	75 mg	50 mg

BID, twice daily

Permanently discontinue if unable to tolerate maximum of three dose reductions or a TAFINLAR 50 mg capsule orally twice daily[1]

Recommended weight-based dosing and dose reductions for MEKINIST tablet administration[2]

Image

MEKINIST

Body Weight	Recommended Paediatric Dose (QD)	First Dose Reduction (QD)	Second Dose Reduction (QD)
26 to 37 kg	1 mg (two 0.5-mg tablets)	0.5 mg	–
38 to 50 kg	1.5 mg (three 0.5-mg tablets)	1 mg	0.5 mg
≥51 kg	2 mg (one 2-mg tablet)	1.5 mg	1 mg

QD, once daily

Permanently discontinue if unable to tolerate a maximum of two dose reductions[2]

Dosing for oral suspension and oral solution administration (patients weighing ≥8 kg)

Recommended weight-based dosing and dose reductions for TAFINLAR dispersible tablets[1]

Image

TAFINLAR

Body Weight (kg)	Daily Dose (BID)	# of 10 mg Tablets (BID)	First Reduction (# of 10 mg Tablets, BID)	Second Reduction (# of 10 mg Tablets, BID)	Third Reduction (# of 10 mg Tablets, BID)
8 to 9	20 mg	2	1	–	–
10 to 13	30 mg	3	2	1	–
14 to 17	40 mg	4	3	2	1
18 to 21	50 mg	5	3	2	1
22 to 25	60 mg	6	4	3	2
26 to 29	70 mg	7	5	4	2
30 to 33	80 mg	8	5	4	3
34 to 37	90 mg	9	6	5	3
38 to 41	100 mg	10	7	5	3
42 to 45	110 mg	11	7	6	4
46 to 50	130 mg	13	9	7	4
≥51	150 mg	15	10	8	5

BID, twice daily

Permanently discontinue if unable to tolerate a maximum of 3 dose reductions or a TAFINLAR 10 mg dispersible tablet orally twice daily[1]

Recommended weight-based dosing and dose reductions for MEKINIST powder for oral solution[2]

Image

MEKINIST

Body Weight (kg)	Recommended Dose Total Volume (QD)	First Dose Reduction (QD)	Second Dose Reduction (QD)
8	6 mL (0.3 mg)	5 mL	3 mL
9	7 mL (0.35 mg)	5 mL	4 mL
10	7 mL (0.35 mg)	5 mL	4 mL
11	8 mL (0.4 mg)	6 mL	4 mL
12 to 13	9 mL (0.45 mg)	7 mL	5 mL
14 to 17	11 mL (0.55 mg)	8 mL	6 mL
18 to 21	14 mL (0.7 mg)	11 mL	7 mL
22 to 25	17 mL (0.85 mg)	13 mL	9 mL
26 to 29	18 mL (0.9 mg)	14 mL	9 mL
30 to 33	20 mL (1 mg)	15 mL	10 mL
34 to 37	23 mL (1.15 mg)	17 mL	12 mL
38 to 41	25 mL (1.25 mg)	19 mL	13 mL
42 to 45	28 mL (1.4 mg)	21 mL	14 mL
46 to 50	32 mL (1.6 mg)	24 mL	16 mL
≥51	40 mL (2 mg)	30 mL	20 mL

QD, once daily

Permanently discontinue if unable to tolerate a maximum of two dose reductions[2]

Image

Image

TAFINLAR and MEKINIST PBS Information: Authority Required. Please refer to PBS Schedule for full authority information for products.

▼ These medicinal products are subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at **www.tga.gov.au/reporting-problems**.

For Australian healthcare professionals only. Please review Product Information before prescribing. For TAFINLAR Product Information, please **click here**. For MEKINIST Product Information, please **click here**. Alternatively, contact med info on 1800 671 203 to access the full Product Information.

Footnotes and References

Abbreviations: AE, adverse event; **CI,** confidence interval; **HR,** hazard ratio; **ORR,** objective response rate; **OS,** overall survival; **PBS,** Pharmaceutical Benefits Scheme; **PFS,** progression-free survival.

References: 1. TAFINLAR (dabrafenib) Australian approved product information. **2.** MEKINIST (trametinib) Australian approved product information. **3.** Bouffet E, et al. N Engl J Med. 2023;389:1108–1120. **4.** Hargrave DR, et al. J Clin Oncol. 2023;41(28):5174–5183. **5.** Lassaletta A, et al. J Clin Oncol. 2017;35(25):2934–2941.

Sydney NSW. Ph (02) 9805 3555. For medical enquiries please contact 1800 671 203 or medinfo.phauno@novartis.com.

AU-28363. July 2025.

Adverse events should be reported.

Adverse events and product complaints should also be reported to Novartis.

For Medical Enquiries, Information Services, Adverse Events and Product Complaints please contact: 1800 671 203 or medinfo.phauno@novartis.com

Colleagues are available from 9:00 to 17:00 from Monday to Friday.
